Kaya Share Price Target 2026 Analyst Forecast Bull and Bear Case

Kaya (NSE: KAYA) is a Dermatology and Skin Care Clinics company trading at Rs 257.33 with a market capitalisation of Rs 1,029 crore. Analysts have set the Kaya share price target at Rs 310 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast for Kaya including sector tailwinds, key risks, and the bull and bear scenarios.

Click Here – Get Free Investment Predictions

Kaya Share Price Target 2026: Key Takeaways

• Kaya share price target 2026: Rs 310 (20% upside from CMP Rs 257.33)
• Bull case: Rs 375 | Bear case: Rs 205
• Ticker: KAYA | Sector: Dermatology and Skin Care Clinics | MCap: Rs 1,029 crore
• 52W range: Rs 180 to Rs 436 | PE: 35x
• Key catalyst: Q4 FY26 results and FY27 earnings recovery confirmation in 2026
• Key risk: FY27 earnings miss or sustained FII outflows from Indian equities

Kaya Company Overview

Kaya (NSE: KAYA) is a Mumbai-based Marico subsidiary operating 150-plus Kaya skin clinics providing medical dermatology, laser, and aesthetic treatments across India and the Middle East, with digital skincare products extending the brand into D2C channels. At CMP Rs 257.33 against a 52 week range of Rs 180 to Rs 436, the stock is trading at a meaningful discount to its 52 week high. The trailing PE is 35x and the Rs 310 analyst target implies approximately 20 percent upside from current levels. Compared to peers in aesthetic healthcare like Strides Pharma and Indraprastha Medical, Kaya is positioned as a potential re-rating candidate on FY27 earnings delivery.

Parameter	Value
NSE Ticker	KAYA
Sector	Dermatology and Skin Care Clinics
CMP (2026)	Rs 257.33
52 Week High	Rs 436
52 Week Low	Rs 180
Market Cap	Rs 1,029 crore
Trailing PE	35x
12-Month Analyst Target	Rs 310
Bull Case Target	Rs 375
Bear Case Target	Rs 205

Why Is the Kaya Share Price Target Set at Rs 310 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Kaya share price target of Rs 310 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for a re-rating. Until FY27 PAT delivery is confirmed, the Rs 310 price objective represents a base case with execution risk attached.

Structural Sector Tailwinds in Dermatology and Skin Care Clinics

The Dermatology and Skin Care Clinics sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Kaya’s position among peers in aesthetic healthcare like Strides Pharma and Indraprastha Medical creates a structural growth runway. Sustained sector outperformance is one of the key conditions for the Rs 375 bull case to materialise, making sector monitoring essential for investors tracking this stock.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs across sectors and stimulating end market demand. For Kaya, lower interest costs improve the EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 310 analyst consensus. This rate environment is a tailwind across the Dermatology and Skin Care Clinics space.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a favourable policy backdrop for Kaya’s Dermatology and Skin Care Clinics operations. Policy support increases the probability of Kaya achieving its FY27 earnings targets, which in turn supports the Rs 310 price objective set by analysts for 2026.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 35x PE, Kaya is positioned as a beneficiary of institutional reallocation into mid-cap and small-cap Indian stocks. Sustained FII inflow is a necessary condition for re-rating the stock toward the Rs 375 bull case scenario.

Kaya Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Kaya Share Price Target

Near-term support for Kaya is anchored near the 52 week low of Rs 180. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors eyeing a near-term entry can use the 52 week low as a key reference while awaiting the FY27 earnings confirmation that would strengthen the case for the full price objective of Rs 310.

12-Month Kaya Share Price Target 2026

The 12-month Kaya share price target 2026 is Rs 310, implying approximately 20 percent upside from CMP Rs 257.33. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Investors can track live price movement on NSE under the ticker KAYA to assess progress toward this target.

Long Term Kaya Share Price Target: FY27 to FY28

The long term Kaya share price target for the FY27 to FY28 period is Rs 375 in the bull case. Full earnings delivery, re-rating toward higher peer multiples among peers in aesthetic healthcare like Strides Pharma and Indraprastha Medical, and sustained institutional buying are the three conditions that need to align for the stock to reach the Rs 375 level over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Kaya in 2026

Bull Case Kaya Share Price Target: Rs 375

The bull case Kaya share price target of Rs 375 materialises when FY27 earnings beat analyst estimates, Dermatology and Skin Care Clinics tailwinds accelerate beyond consensus, and FII flows return strongly to Indian equities. Under this scenario, Kaya re-rates toward higher peer multiples, making Rs 375 achievable within FY28. The current gap between CMP Rs 257.33 and Rs 375 represents approximately 45 percent potential upside.

Bear Case Kaya Share Price Target: Rs 205

The bear case Kaya share price target of Rs 205 materialises if FY27 earnings disappoint, management guides below expectations, or sustained FII outflows depress the broader mid-cap market. Under this scenario, the stock risks testing the 52 week low support near Rs 180, and investors should reassess the investment thesis before adding more capital.

Scenario	Target	Key Conditions
Bull Case	Rs 375	FY27 earnings beat, sector re-rating, FII inflows
Base Case (Analyst Target)	Rs 310	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 205	FY27 miss, guidance cut, FII outflows persist

Key Risks That Could Derail the Kaya 2026 Price Objective

Global Macro and US Tariff Headwinds

The prolonged tariff tension triggered by the US reciprocal tariff announcement in 2026 has reduced FII risk appetite for Indian equities. A global demand slowdown or escalation in trade tensions remains the most prominent macro risk to the Kaya share price target of Rs 310 and could push the stock toward the bear case of Rs 205.

FY27 Earnings Miss and Guidance Risk

Any FY27 earnings miss or downward guidance revision by Kaya’s management would compress valuation multiples. This is the most direct company-specific risk to the Rs 310 analyst price objective. Investors should monitor quarterly results and management commentary closely, especially any signals about demand environment, pricing power, or margin compression in the Dermatology and Skin Care Clinics segment.

Competitive Intensity Among Dermatology and Skin Care Clinics Peers

Intensifying competition from peers in aesthetic healthcare like Strides Pharma and Indraprastha Medical could compress Kaya’s market share and pricing power over the medium term. This structural risk must be weighed when assessing how defensible the earnings trajectory that underpins the Rs 310 analyst target truly is, particularly as new entrants and imports from China disrupt established market structures.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level operational improvement. For smaller market cap stocks, liquidity constraints can amplify drawdowns significantly. Investors should size positions carefully and maintain stop losses to protect capital if the broader market de-rating continues through FY27.

How to Invest in Kaya: A Step-by-Step Approach

Check the Univest Screener for live data

Before considering any investment based on the Kaya share price target of Rs 310, review the company’s Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, operating margin trends, debt levels, and management commentary on Dermatology and Skin Care Clinics sector demand and competition.

Open a Demat and trading account with a SEBI registered stockbroker to trade Kaya (NSE: KAYA) with regulatory protection. Complete KYC, and before executing any order, study the competitive landscape among peers in aesthetic healthcare like Strides Pharma and Indraprastha Medical to assess whether Kaya’s competitive position justifies the Rs 310 valuation.

Plan your entry using technical and fundamental triggers. The 52 week low of Rs 180 acts as a key support reference. A confirmed FY27 earnings uptick combined with positive guidance would validate the entry case. Always set a pre-defined stop loss below the 52 week low to limit downside.

Maintain position sizing discipline. Restrict any single stock to 3 to 5 percent of your total equity portfolio. This is especially important in the Dermatology and Skin Care Clinics space where sectoral cycles, regulatory changes, and commodity price swings can amplify volatility beyond initial expectations.

Always consult a SEBI registered financial advisor before making investment decisions based on any analyst price target or market commentary. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Kaya’s live share price and receive daily stock recommendations from SEBI registered analysts.

FAQs on Kaya Share Price Target 2026

What is the Kaya share price target for 2026?

Ans. The Kaya share price target 2026 is Rs 310, implying approximately 20 percent upside from CMP Rs 257.33. The bull case estimate is Rs 375 and the bear case is Rs 205.

What was the Kaya share price target for 2025?

Ans. The 2025 price target for Kaya was based on FY26 earnings projections. The current 2026 analyst consensus stands at Rs 310, reflecting FY27 growth potential from CMP Rs 257.33.

Is Kaya a good investment at Rs 257.33?

Ans. At Rs 257.33, Kaya offers potential upside toward Rs 310 if FY27 earnings recover as projected. Whether the stock is a good buy depends on individual risk appetite, investment horizon, and portfolio goals. Consult a SEBI registered financial advisor before investing.

What are the key risks to the Kaya share price target 2026?

Ans. Key risks to the Kaya share price target of Rs 310 include FY27 earnings miss, global tariff headwinds, sustained FII outflows, and competitive pressure in the Dermatology and Skin Care Clinics sector. Monitoring quarterly results closely is essential.

What is the 52 week high and low of Kaya?

Ans. The 52 week high of Kaya is Rs 436 and the 52 week low is Rs 180. At CMP Rs 257.33, the stock is trading below its 52 week high and offers upside potential toward the Rs 310 analyst price objective.

What are the main growth catalysts for Kaya in 2026?

Ans. Primary growth catalysts for Kaya in 2026 include FY27 PAT recovery, Dermatology and Skin Care Clinics sector tailwinds, RBI rate cuts reducing cost of capital, Union Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Kaya compare to its peers?

Ans. Kaya operates in Dermatology and Skin Care Clinics alongside peers in aesthetic healthcare like Strides Pharma and Indraprastha Medical. At CMP Rs 257.33 with MCap Rs 1,029 crore, the company is positioned as a potential re-rating candidate toward the Kaya share price target of Rs 310 on FY27 earnings delivery.

What is the Kaya share price target for 2027?

Ans. The long-term Kaya share price target for FY27 to FY28 is Rs 375 in the bull case, assuming continued earnings growth, sector re-rating, and sustained FII inflows. Consult a SEBI registered financial advisor for personalised guidance.